A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Genetic biomarkers to guide poly (ADP-ribose) polymerase inhibitor precision treatment of prostate cancer
Tekijät: Varnai Reka, Sipeky Csilla
Kustantaja: FUTURE MEDICINE LTD
Julkaisuvuosi: 2020
Journal: Pharmacogenomics
Tietokannassa oleva lehden nimi: PHARMACOGENOMICS
Lehden akronyymi: PHARMACOGENOMICS
Vuosikerta: 21
Numero: 15
Aloitussivu: 1101
Lopetussivu: 1115
Sivujen määrä: 15
ISSN: 1462-2416
eISSN: 1744-8042
DOI: https://doi.org/10.2217/pgs-2020-0019
Tiivistelmä
Precision therapy for a subgroup of genetically defined metastatic castration-resistant prostate cancer patients may become a reality in the near future. DNA damage repair gene mutated prostate cancer might be vulnerable to treatment with PARP inhibitors (PARPi). PARPi clinical trials for prostate cancer investigate both germline and somatic genomic alterations of 43 genes for the applicability as genomic biomarker of PARPi sensitivity. Clinical trials with preliminary results show that BRCA2 and BRCA1, but also ATM, additionally BRIP1, FANCA, CDK12 and PALB2 may affect clinical end points, and may be potential candidates for genome guided patient selection in PARP inhibitor treatment of prostate cancer.
Precision therapy for a subgroup of genetically defined metastatic castration-resistant prostate cancer patients may become a reality in the near future. DNA damage repair gene mutated prostate cancer might be vulnerable to treatment with PARP inhibitors (PARPi). PARPi clinical trials for prostate cancer investigate both germline and somatic genomic alterations of 43 genes for the applicability as genomic biomarker of PARPi sensitivity. Clinical trials with preliminary results show that BRCA2 and BRCA1, but also ATM, additionally BRIP1, FANCA, CDK12 and PALB2 may affect clinical end points, and may be potential candidates for genome guided patient selection in PARP inhibitor treatment of prostate cancer.
Turun yliopiston Tutkimustietojärjestelmän portaali